08:13 AM EDT, 10/24/2024 (MT Newswires) -- Semaglutide, the active ingredient in Novo Nordisk's ( NVO ) Ozempic and Wegovy drugs, was associated with "significantly reduced risk" for first-time diagnosis of Alzheimer's disease, according to a study published Thursday by the Alzheimer's Association.

"Semaglutide was associated with 40% to 70% reduced risks of first-time [Alzheimer's disease] diagnosis in [type 2 diabetes mellitus] patients compared to other antidiabetic medications, including other [glucagon-like peptide receptor agonists]," the study said.

Price: 115.18, Change: -0.56, Percent Change: -0.48